Contract manufacturer Curia names new CEO

23 Mar 2023
endpts.com
VaccineExecutive Change
The Albany, NY-based contract manufacturer Curia has named Philip Macnabb as its new CEO, succeeding John Ratliff, who has been at the helm since 2019. According to Macnabb’s LinkedIn profile , he previously served as CEO of the healthcare company Epselon Global, and before that was president of Sotera Health’s Sterigenics. His resume is dotted with other executive roles, including CFO of Fairmount Food Group. Macnabb told Endpoints News in an email that he was inspired by Curia’s mission to improve patients’ lives and its pivot during the pandemic to support the production of vaccines and treatments. “But the truth is our scientific contribution routinely impacts millions of patients across multiple disease and therapeutic areas, week in and week out,” he said. “I will focus on improving the customer experience and ease of doing business with Curia.” Macnabb also noted that the company has been growing over the past few years as it has embarked on physical expansions in New York and New Mexico as well as bringing two manufacturers, Integrity Bio, and LakePharma into its fold last year . The CDMO, rebranded from AMRI in 2021, manufactures a wide range of products including active pharmaceutical ingredients, biologics, small molecules, ADC therapies and monoclonal antibodies, among other products. The company was also chosen to help manufacture AstraZeneca’s Covid-19 vaccineCovid-19 vaccine in 2020. Macnabb noted that the CDMO market is “attractive” and anticipates continued growth in the market, especially around R&D and outsourcing. He pointed to Curia’s strengths in small molecule and biologics as putting the company in a good position for the future.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.